Drug Patents owned by Eisai Inc

1. Drug name - ARICEPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481565 EISAI INC Method for stabilizing anti-dementia drug Oct, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
23MG TABLET;ORAL Prescription

2. Drug name - BANZEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(a month from now)

CN1217716A EISAI INC Improved Crystalline Body Of Medicine
Jun, 2018

(4 years ago)

CN1132820C EISAI INC Improved Crystalline Body Of Medicine
Jun, 2018

(4 years ago)

CN1572789A EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

CN1298708C EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Use Thereof
Jun, 2018

(4 years ago)

CN1259127A EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

CN1159300C EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

EP994864B1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jun, 2018

(4 years ago)

EP994864A1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jun, 2018

(4 years ago)

EP994863B1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

EP994863A1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic May, 2023

(7 months from now)

Drugs and Companies using RUFINAMIDE ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;ORAL Prescription

3. Drug name - DAYVIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

CN103153963A EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

CN103153963B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN201303338P1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

IN387588B EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A4 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350A1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

EP2626350B1 EISAI INC Cyclopropane Compound
Sep, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia Oct, 2035

(13 years from now)

Drugs and Companies using LEMBOREXANT ingredient

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

4. Drug name - FYCOMPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2022

(3 months ago)

US8772497 EISAI INC Method for producing 1, 2-dihydropyridine-2-one compound
Jul, 2026

(3 years from now)

CN1436172A EISAI INC 1, 2-Dihydro-Pyridine Compound And Preparation Method And Use Thereof
Jun, 2021

(1 year, 3 months ago)

CN1245386C EISAI INC 1, 2-Dihydro-Pyridine Compound And Preparation Method And Use Thereof
Jun, 2021

(1 year, 3 months ago)

CN101914057A EISAI INC Crystal Of 1,2-Dihydropyridine Compound
Jul, 2025

(2 years from now)

CN101544599B EISAI INC Crystal Of 1,2-Dihydropyridine Compound
Jul, 2025

(2 years from now)

CN1942443A EISAI INC The Crystal Of 1,2-Dihydropyridine Compound And The Manufacturing Method
Jul, 2025

(2 years from now)

CN102382047B EISAI INC 1, 2-Dihydro-Pyridine Compound Crystal
Jul, 2025

(2 years from now)

CN101914057B EISAI INC 1, 2-Dihydro-Pyridine Compound Crystal
Jul, 2025

(2 years from now)

CN101544599A EISAI INC Crystal Of 1,2-Dihyropyridin Compound
Jul, 2025

(2 years from now)

CN1942443B EISAI INC 1, 2-Dihydro-Pyridine Compound Crystal And Preparation Method Thereof
Jul, 2025

(2 years from now)

CN102382047A EISAI INC Crystal Of 1,2-Dihydropyridine Compound
Jul, 2025

(2 years from now)

IN200600561P3 EISAI INC 1-2 Dihydropyridine Compounds, Process For Preparation Of The Same And Use Threof
Jun, 2021

(1 year, 3 months ago)

IN202869B EISAI INC Production Process Of 1,2-Dihydropyridine Compounds
Jun, 2021

(1 year, 3 months ago)

IN291766B EISAI INC 1-2 Dihydropyridine Compounds, Process For Preparation Of The Same And Use Thereof
Jun, 2021

(1 year, 3 months ago)

EP1764361B1 EISAI INC Crystal Of 1,2-Dihydropyridine Compound And Method For Producing Same
Jul, 2025

(2 years from now)

EP1772450A4 EISAI INC Method For Producing 1,2-Dihydropyridine-2-One Compound
Jul, 2025

(2 years from now)

EP1764361A1 EISAI INC Crystal Of 1,2-Dihydropyridine Compound And Method For Producing Same
Jul, 2025

(2 years from now)

EP1764361A4 EISAI INC Crystal Of 1,2-Dihydropyridine Compound And Method For Producing Same
Jul, 2025

(2 years from now)

EP1772450B1 EISAI INC Method For Producing 1,2-Dihydropyridine-2-One Compound
Jul, 2025

(2 years from now)

EP1772450A1 EISAI INC Method For Producing 1,2-Dihydropyridine-2-One Compound
Jul, 2025

(2 years from now)

EP1300396A1 EISAI INC 1,2-Dihydropyridine Compounds, Process For Preparation Of The Same And Use Thereof
Jun, 2026

(3 years from now)

EP1300396B1 EISAI INC 1,2-Dihydropyridine Compounds, Process For Preparation Of The Same And Use Thereof
Jun, 2026

(3 years from now)

EP1300396A4 EISAI INC 1,2-Dihydropyridine Compounds, Process For Preparation Of The Same And Use Thereof
Jun, 2026

(3 years from now)

Drugs and Companies using PERAMPANEL ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG/ML SUSPENSION;ORAL Prescription

5. Drug name - HALAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(9 months from now)

CN1312804A EISAI INC Macrocyclic Analogs And Methods Of Use And Preparation Method
Jun, 2019

(3 years ago)

CN1216051C EISAI INC Macrocyclic Analogs And Methods Of Use And Preparation Method
Jun, 2019

(3 years ago)

EP2277873A1 EISAI INC Intermediate Compound For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP2272839B1 EISAI INC Intermediate Compounds For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP2272839A1 EISAI INC Intermediate Compounds For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP2277873B1 EISAI INC Intermediate Compound For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP2272840A1 EISAI INC Intermediate Compound For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP2272840B1 EISAI INC Intermediate Compound For The Preparation Of Halichondrin Analogs
Jun, 2019

(3 years ago)

EP1087960B1 EISAI INC Macrocyclic Analogs And Methods Of Their Use And Preparation
Jun, 2024

(1 year, 8 months from now)

EP1087960A4 EISAI INC Macrocyclic Analogs And Methods Of Their Use And Preparation
Jun, 2024

(1 year, 8 months from now)

EP1087960A1 EISAI INC Macrocyclic Analogs And Methods Of Their Use And Preparation
Jun, 2024

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B Jan, 2027

(4 years from now)

Drugs and Companies using ERIBULIN MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1MG/2ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription

6. Drug name - LENVIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(3 years from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(3 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

CN101024627A EISAI INC Aromatic-Ring Derivative Including Nitrogen
Nov, 2010

(11 years ago)

CN101029022A EISAI INC Preparing Method Of Aromaticring Ramification Containing Nitrogen
Oct, 2021

(11 months ago)

CN1478078A EISAI INC Aromatic-Ring Derivative Including Nitrogen
Oct, 2021

(11 months ago)

CN1308310C EISAI INC Aromatic-Ring Derivative Including Nitrogen
Oct, 2021

(11 months ago)

CN101029022B EISAI INC Nitrogen-Containing Aromatic Ring Derivatives And Process For Their Preparation
Oct, 2021

(11 months ago)

CN101337931B EISAI INC Of Mesilate Of Acetic Acid Solvate Crystal (I) And Preparation Method Thereof
Dec, 2024

(2 years from now)

CN101337931A EISAI INC Mesilate And Acetic Acid To Object And Mesylate Is Crystal (I) And Its Preparation Method
Dec, 2024

(2 years from now)

CN101337933B EISAI INC Quinoline-Carboxamide Mesylate Crystal (A) And Its Preparation Method
Dec, 2024

(2 years from now)

CN101337933A EISAI INC Crystal (A) Of Mesilate Of Quinolinecarboxamide And Producing Method Thereof
Dec, 2024

(2 years from now)

CN100569753C EISAI INC 4 - (3 - (-4-(Cyclopropylaminocarbonyl) Aminophenoxy)--7 - Methoxy - -6 - Mesilate Of Crystal (C) And Preparation Method Thereof
Dec, 2024

(2 years from now)

CN101337932B EISAI INC Quinoline-Carboxamide Of Crystalline Form Of (B) And Its Preparation Method
Dec, 2024

(2 years from now)

CN1890220A EISAI INC A Crystalline Of The Salt Form Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Aminophenoxy)-7-Methoxy-6-Quinolinecarboxamide Or The Solvate Of The Salt And A Process For Preparing The Same
Dec, 2024

(2 years from now)

CN101337932A EISAI INC Crystal (B) Of Mesilate Of Quinolinecarboxamide And Producing Method Thereof
Dec, 2024

(2 years from now)

CN106660964A EISAI INC Quinoline Derivative With High Purity And Production Method Thereof
Aug, 2035

(12 years from now)

CN106660964B EISAI INC High Purity Quinoline Derivatives And Process For Producing The Same
Aug, 2035

(12 years from now)

IN236500B EISAI INC A Crystalline From Of The Salt Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Amino-Phenoxy)-7-Methoxy-6-Quinolinecarboxamide
Dec, 2024

(2 years from now)

IN200602572P4 EISAI INC A Crystalline From Of The Salt Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Amino-Phenoxy)-7-Methoxy-6-Quinolinecarboxamide Or The Solvate Of The Salt And A Process For Preparing The Same
Dec, 2024

(2 years from now)

EP1506962A2 EISAI INC Nitrogen-Containing Aromatic Heterocycles
Oct, 2021

(11 months ago)

EP1506962A3 EISAI INC Nitrogen-Containing Aromatic Heterocycles
Oct, 2021

(11 months ago)

EP1506962B1 EISAI INC Nitrogen-Containing Aromatic Heterocycles
Oct, 2021

(11 months ago)

EP1777218A1 EISAI INC Process For The Preparation Of 4-Phenoxy Quinoline Derivatives
Oct, 2021

(11 months ago)

EP1777218B1 EISAI INC Process For The Preparation Of 4-Phenoxy Quinoline Derivatives
Oct, 2021

(11 months ago)

EP1698623A1 EISAI INC Crystal Of Salt Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Amino-Phenoxy)-7-Methoxy-6-Quinolinecarboxamide Or Of Solvate Thereof And Processes For Producing These
Dec, 2024

(2 years from now)

EP1698623B1 EISAI INC Crystal Of Salt Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Amino-Phenoxy)-7-Methoxy-6-Quinolinecarboxamide Or Of Solvate Thereof And Processes For Producing These
Dec, 2024

(2 years from now)

EP1698623A4 EISAI INC Crystal Of Salt Of 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Amino-Phenoxy)-7-Methoxy-6-Quinolinecarboxamide Or Of Solvate Thereof And Processes For Producing These
Dec, 2024

(2 years from now)

EP1415987A4 EISAI INC Nitrogenous Aromatic Ring Compounds
Oct, 2026

(4 years from now)

EP1415987A1 EISAI INC Nitrogenous Aromatic Ring Compounds As Anti Cancer Agents
Oct, 2026

(4 years from now)

EP1415987B1 EISAI INC Nitrogenous Aromatic Ring Compounds As Anti Cancer Agents
Oct, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer Jul, 2027

(4 years from now)

Drugs and Companies using LENVATINIB MESYLATE ingredient

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription

7. Drug name - LUSEDRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6204257 EISAI INC Water soluble prodrugs of hindered alcohols
Jul, 2022

(3 months ago)

CN1680402A EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenol
Jul, 2008

(14 years ago)

CN1198834C EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenol
Sep, 2017

(5 years ago)

CN1357000A EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenol
Sep, 2017

(5 years ago)

IN200100116P1 EISAI INC Water Soluble Prodrugs Of Hindered Alcohols
Aug, 2019

(3 years ago)

IN241214B EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenols
Aug, 2019

(3 years ago)

IN200100117P1 EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenols
Aug, 2019

(3 years ago)

IN238820B EISAI INC Water Soluble Prodrugs Of Hindered Alcohols Or Phenols
Aug, 2019

(3 years ago)

EP1102776B1 EISAI INC Water Soluble Prodrugs Of Hindered Phenols
Aug, 2019

(3 years ago)

EP1102776A1 EISAI INC Water Soluble Prodrugs Of Hindered Phenols
Aug, 2019

(3 years ago)

Drugs and Companies using FOSPROPOFOL DISODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1050MG/30ML (35MG/ML) SOLUTION;INTRAVENOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.